<--- Back to Details
First PageDocument Content
Arthritis / Connective tissue diseases / COX-2 inhibitors / Non-steroidal anti-inflammatory drugs / Celecoxib / G. D. Searle & Company / Juvenile idiopathic arthritis / Rheumatoid arthritis / Health / Medicine / Pfizer
Date: 2006-11-14 08:23:20
Arthritis
Connective tissue diseases
COX-2 inhibitors
Non-steroidal anti-inflammatory drugs
Celecoxib
G. D. Searle & Company
Juvenile idiopathic arthritis
Rheumatoid arthritis
Health
Medicine
Pfizer

Disclosure Document for an 18 U

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 12,82 KB

Share Document on Facebook

Similar Documents

Superior drug derivatives via late stage hydroxylation Microsomal and microbial biotransformation of drugs There is increasing focus on thorough investigation of drug metabolites, exemplified by Pfizer’s routine biocat

DocID: 1v0tF - View Document

Plasma Protein Binding: Friend or Foe in Drug Discovery? Kevin Beaumont and Tristan Maurer Pharmacokinetics, Dynamics and Metabolism Pfizer Worldwide Research and Development Memorial Drive, Cambridge

DocID: 1uQg4 - View Document

Dárci 2010 Finanční dary SAZKA Praha ROCHE Praha Pfizer s.r.o. Praha Novartis s.r.o., Praha

DocID: 1tU5V - View Document

Clonazepam 2 mg costo. Getting to know Microsoft Money for Lconazepam Clonazepam 2 mg costo takes only pfizer terramycin la few minutes, and its time well spent. Hutton CThe Meteorology And Climate Of Tropical A

DocID: 1tffN - View Document

JP Morgan Healthcare Conference Advancing Differentiated High Value Products Mikael Dolsten, M.D., Ph.D. President Worldwide R&D January 13, 2015

DocID: 1t2Pn - View Document